Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Lymphangiogenesis-independent resolution of experimental edema.

Ongstad EL, Bouta EM, Roberts JE, Uzarski JS, Gibbs SE, Sabel MS, Cimmino VM, Roberts MA, Goldman J.

Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H46-54. doi: 10.1152/ajpheart.00008.2010. Epub 2010 Mar 5.

2.

The resolution of lymphedema by interstitial flow in the mouse tail skin.

Uzarski J, Drelles MB, Gibbs SE, Ongstad EL, Goral JC, McKeown KK, Raehl AM, Roberts MA, Pytowski B, Smith MR, Goldman J.

Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1326-34. doi: 10.1152/ajpheart.00900.2007. Epub 2008 Jan 18.

3.

Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F.

Breast Cancer Res. 2011 Jun 21;13(3):R66. doi: 10.1186/bcr2903.

4.

VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B.

Onimaru M, Yonemitsu Y, Fujii T, Tanii M, Nakano T, Nakagawa K, Kohno R, Hasegawa M, Nishikawa S, Sueishi K.

Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1685-96. doi: 10.1152/ajpheart.00015.2009. Epub 2009 Sep 4.

5.

Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.

Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, Skobe M, Boardman KC, Swartz MA.

J Natl Cancer Inst. 2005 Jan 5;97(1):14-21.

PMID:
15632376
6.

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.

Cancer Res. 2008 Jun 15;68(12):4754-62. doi: 10.1158/0008-5472.CAN-07-5809.

7.

Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.

Davydova N, Harris NC, Roufail S, Paquet-Fifield S, Ishaq M, Streltsov VA, Williams SP, Karnezis T, Stacker SA, Achen MG.

J Biol Chem. 2016 Dec 30;291(53):27265-27278. doi: 10.1074/jbc.M116.736801. Epub 2016 Nov 16.

8.

Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.

Goldman J, Rutkowski JM, Shields JD, Pasquier MC, Cui Y, Schmökel HG, Willey S, Hicklin DJ, Pytowski B, Swartz MA.

FASEB J. 2007 Apr;21(4):1003-12. Epub 2007 Jan 8. Erratum in: FASEB J. 2007 Jun;21(8):1942.

PMID:
17210781
9.

VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.

Visuri MT, Honkonen KM, Hartiala P, Tervala TV, Halonen PJ, Junkkari H, Knuutinen N, Ylä-Herttuala S, Alitalo KK, Saarikko AM.

Angiogenesis. 2015 Jul;18(3):313-26. doi: 10.1007/s10456-015-9469-2. Epub 2015 May 28.

PMID:
26018927
10.

Regulation of lymphatic capillary regeneration by interstitial flow in skin.

Goldman J, Conley KA, Raehl A, Bondy DM, Pytowski B, Swartz MA, Rutkowski JM, Jaroch DB, Ongstad EL.

Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2176-83. Epub 2006 Dec 22.

11.

Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.

Chung ES, Chauhan SK, Jin Y, Nakao S, Hafezi-Moghadam A, van Rooijen N, Zhang Q, Chen L, Dana R.

Am J Pathol. 2009 Nov;175(5):1984-92. doi: 10.2353/ajpath.2009.080515. Epub 2009 Oct 1.

12.

Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation.

Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K, Detmar M.

J Exp Med. 2010 Sep 27;207(10):2255-69. doi: 10.1084/jem.20100559. Epub 2010 Sep 13.

13.

Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis.

Kajiya K, Sawane M, Huggenberger R, Detmar M.

J Invest Dermatol. 2009 May;129(5):1292-8. doi: 10.1038/jid.2008.351. Epub 2008 Nov 13.

14.

Functional analyses of the bone marrow kinase in the X chromosome in vascular endothelial growth factor-induced lymphangiogenesis.

Jones D, Xu Z, Zhang H, He Y, Kluger MS, Chen H, Min W.

Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2553-61. doi: 10.1161/ATVBAHA.110.214999. Epub 2010 Sep 23.

16.

RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.

Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y.

Eur J Cancer. 2011 Oct;47(15):2353-63. doi: 10.1016/j.ejca.2011.05.006. Epub 2011 Jun 15.

PMID:
21680174
17.

Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.

Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M.

Cancer Res. 2006 Mar 1;66(5):2650-7.

18.

Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.

Lohela M, Heloterä H, Haiko P, Dumont DJ, Alitalo K.

Am J Pathol. 2008 Dec;173(6):1891-901. doi: 10.2353/ajpath.2008.080378. Epub 2008 Nov 6.

19.

Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.

Yang H, Kim C, Kim MJ, Schwendener RA, Alitalo K, Heston W, Kim I, Kim WJ, Koh GY.

Mol Cancer. 2011 Apr 11;10:36. doi: 10.1186/1476-4598-10-36.

20.

Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation.

Zheng Y, Murakami M, Takahashi H, Yamauchi M, Kiba A, Yamaguchi S, Yabana N, Alitalo K, Shibuya M.

Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2019-26. Epub 2006 Jun 22.

Supplemental Content

Support Center